Neuroprotective potential of CB 1 receptor agonists in an in vitro model of Huntington's disease

British Journal of Pharmacology

Volumn 160, Issue 3, 2010, Pages 747-761

  Scotter, E L ^a   Goodfellow, C E ^a   Graham, E S ^a   Dragunow, M ^a   Glass, M ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Aggregate; Cannabinoid; CB 1; ERK; Huntingtin; Huntington's disease; Neuroprotection

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; BAY 593074; CANNABINOID 1 RECEPTOR; CANNABINOID RECEPTOR AGONIST; CYCLIC AMP; DEXANABINOL; HUNTINGTIN; MITOGEN ACTIVATED PROTEIN KINASE; PERTUSSIS TOXIN; UNCLASSIFIED DRUG; UO 126; 1,3 BUTADIENE DERIVATIVE; 1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; DOPAMINE RECEPTOR; DRUG DERIVATIVE; GUANINE NUCLEOTIDE BINDING PROTEIN ALPHA SUBUNIT; HUNTINGTIN PROTEIN, RAT; MITOGEN ACTIVATED PROTEIN KINASE 3; NERVE PROTEIN; NEUROPROTECTIVE AGENT; NITRILE; NUCLEAR PROTEIN; PIPERIDINE DERIVATIVE; PYRAZOLE DERIVATIVE; RIMONABANT; TETRAHYDROCANNABINOL;

ANIMAL CELL; ARTICLE; CELL DEATH; CELL SURVIVAL; CONTROLLED STUDY; CYTOTOXICITY; DRUG MECHANISM; DRUG RECEPTOR BINDING; ENZYME PHOSPHORYLATION; HUNTINGTON CHOREA; IN VITRO STUDY; NEUROPROTECTION; NONHUMAN; PHEOCHROMOCYTOMA CELL; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN EXPRESSION; RAT; SIGNAL TRANSDUCTION; WILD TYPE; ANIMAL; CELL LINE; CELL STRAIN; CEREBELLUM; CULTURE TECHNIQUE; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; HUMAN; METABOLISM; MOUSE;

ANIMALS; BUTADIENES; CELL CULTURE TECHNIQUES; CELL DEATH; CELL LINE, TRANSFORMED; CEREBELLUM; CYCLIC AMP; GTP-BINDING PROTEIN ALPHA SUBUNITS; HUMANS; HUNTINGTON DISEASE; MICE; MITOGEN-ACTIVATED PROTEIN KINASE 3; NERVE TISSUE PROTEINS; NEUROPROTECTIVE AGENTS; NITRILES; NUCLEAR PROTEINS; PC12 CELLS; PERTUSSIS TOXIN; PIPERIDINES; PYRAZOLES; RATS; RECEPTOR, CANNABINOID, CB1; RECEPTORS, DOPAMINE; TETRAHYDROCANNABINOL;

EID: 77952661567     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2010.00773.x     Document Type: Article

References (50)

1. Aiken CT, Tobin AJ, Schweitzer ES (2004). A cell-based screen for drugs to treat Huntington's disease. Neurobiol Dis 16 : 546 555.
2. Alexander SP, Mathie A, Peters JA (2008). Guide to Receptors and Channels (GRAC), 3rd edition. Br J Pharmacol 153 : S1 S209.
3. Andersson M, Usiello A, Borgkvist A, Pozzi L, Dominguez C, Fienberg AA et al. (2005). Cannabinoid action depends on phosphorylation of dopamine- and cAMP-regulated phosphoprotein of 32 kDa at the protein kinase A site in striatal projection neurons. J Neurosci 25 : 8432 8438.
4. Biegon A, Kerman IA (2001). Autoradiographic study of pre- and postnatal distribution of cannabinoid receptors in human brain. Neuroimage 14 : 1463 1468.
5. Bonhaus DW, Chang LK, Kwan J, Martin GR (1998). Dual activation and inhibition of adenylyl cyclase by cannabinoid receptor agonists: evidence for agonist-specific trafficking of intracellular responses. J Pharmacol Exp Ther 287 : 884 888.
6. Caughey B, Lansbury PT (2003). Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders. Annu Rev Neurosci 26 : 267 298.
7. Caunt CJ, Finch AR, Sedgley KR, McArdle CA (2006). Seven-transmembrane receptor signalling and ERK compartmentalization. Trends Endocrinol Metab 17 : 276 283.
8. Charvin D, Vanhoutte P, Pages C, Borrelli E, Caboche J (2005). Unraveling a role for dopamine in Huntington's disease: the dual role of reactive oxygen species and D2 receptor stimulation. Proc Natl Acad Sci USA 102 : 12218 12223.
9. Chen S, Berthelier V, Yang W, Wetzel R (2001). Polyglutamine aggregation behavior in vitro supports a recruitment mechanism of cytotoxicity. J Mol Biol 311 : 173 182.
10. Daumas F, Destainville N, Millot C, Lopez A, Dean D, Salome L (2003). Confined diffusion without fences of a G-protein-coupled receptor as revealed by single particle tracking. Biophys J 84 : 356 366.
11. De Vry J, Denzer D, Reissmueller E, Eijckenboom M, Heil M, Meier H et al. (2004). 3-[2-cyano-3-(trifluoromethyl)phenoxy]phenyl-4,4,4-trifluoro-1- butanesulfo nate (BAY 59-3074): a novel cannabinoid Cb1/Cb2 receptor partial agonist with antihyperalgesic and antiallodynic effects. J Pharmacol Exp Ther 310 : 620 632.
12. van Dellen A, Blakemore C, Deacon R, York D, Hannan AJ (2000). Delaying the onset of Huntington's in mice. Nature 404 : 721 722.
13. Ebisuya M, Kondoh K, Nishida E (2005). The duration, magnitude and compartmentalization of ERK MAP kinase activity: mechanisms for providing signaling specificity. J Cell Sci 118 : 2997 3002.
14. Ferrante RJ, Kowall NW, Beal MF, Richardson EP Jr., Bird ED, Martin JB (1985). Selective sparing of a class of striatal neurons in Huntington's disease. Science 230 : 561 563.
15. Glass M, Felder CC (1997). Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors augments cAMP accumulation in striatal neurons: evidence for a Gs linkage to the CB1 receptor. J Neurosci 17 : 5327 5333.
16. Glass M, Northup JK (1999). Agonist selective regulation of G proteins by cannabinoid CB1 and CB2 receptors. Mol Pharmacol 56 : 1362 1369.
17. Glass M, Dragunow M, Faull RL (1997). Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. Neuroscience 77 : 299 318.
18. Glass M, Dragunow M, Faull RL (2000). The pattern of neurodegeneration in Huntington's disease: a comparative study of cannabinoid, dopamine, adenosine and GABA(A) receptor alterations in the human basal ganglia in Huntington's disease. Neuroscience 97 : 505 519.
19. Glass M, van Dellen A, Blakemore C, Hannan AJ, Faull RLM (2004). Delayed onset of Huntington's disease in mice in an enriched environment correlates with delayed loss of cannabinoid CB1 receptors. Neuroscience 123 : 207 212.
20. Gonzalez RJ, Tarloff JB (2001). Evaluation of hepatic subcellular fractions for Alamar blue and MTT reductase activity. Toxicol In Vitro 15 : 257 259.
21. Graham ES, Ball N, Scotter EL, Narayan P, Dragunow M, Glass M (2006). Induction of Krox-24 by endogenous cannabinoid type 1 receptors in Neuro2A cells is mediated by the MEK-ERK MAPK pathway and is suppressed by the phosphatidylinositol 3-kinase pathway. J Biol Chem 281 : 29085 29095.
22. Graveland GA, Williams RS, DiFiglia M (1985). Evidence for degenerative and regenerative changes in neostriatal spiny neurons in Huntington's disease. Science 227 : 770 773.
23. Grimsey NL, Narayan PJ, Dragunow M, Glass M (2008). A novel high-throughput assay for the quantitative assessment of receptor trafficking. Clin Exp Pharmacol Physiol 35 : 1377 1382.
24. Hillard CJ, Edgemond WS, Campbell WB (1995). Characterization of ligand binding to the cannabinoid receptor of rat brain membranes using a novel method: application to anandamide. J Neurochem 64 : 677 683.
25. Hoffner G, Island M-L, Djian P (2005). Purification of neuronal inclusions of patients with Huntington's disease reveals a broad range of N-terminal fragments of expanded huntingtin and insoluble polymers. J Neurochem 95 : 125 136.
26. Houslay MD (1995). Compartmentalization of cyclic AMP phosphodiesterases, signalling 'crosstalk', desensitization and the phosphorylation of Gi-2 add cell specific personalization to the control of the levels of the second messenger cyclic AMP. Adv Enzyme Regul 35 : 303 338.
27. Howlett AC, Qualy JM, Khachatrian LL (1986). Involvement of Gi in the inhibition of adenylate cyclase by cannabimimetic drugs. Mol Pharmacol 29 : 307 313.
28. Jin K, LaFevre-Bernt M, Sun Y, Chen S, Gafni J, Crippen D et al. (2005). FGF-2 promotes neurogenesis and neuroprotection and prolongs survival in a transgenic mouse model of Huntington's disease. Proc Natl Acad Sci USA 102 : 18189 18194.
29. Kazantsev A, Preisinger E, Dranovsky A, Goldgaber D, Housman D (1999). Insoluble detergent-resistant aggregates form between pathological and nonpathological lengths of polyglutamine in mammalian cells. Proc Natl Acad Sci USA 96 : 11404 11409.
30. Kearn CS, Blake-Palmer K, Daniel E, Mackie K, Glass M (2005). Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors enhances heterodimer formation: a mechanism for receptor cross-talk? Mol Pharmacol 67 : 1697 1704.
31. Laemmli UK (1970). Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227 : 680 685.
32. de Lago E, Fernandez-Ruiz J, Ortega-Gutierrez S, Cabranes A, Pryce G, Baker D et al. (2006). UCM707, an inhibitor of the anandamide uptake, behaves as a symptom control agent in models of Huntington's disease and multiple sclerosis, but fails to delay/arrest the progression of different motor-related disorders. Eur Neuropsychopharmacol 16 : 7 18.
33. Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, Liosatos M et al. (1998). Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci USA 95 : 6448 6453.
34. Lastres-Becker I, Bizat N, Boyer F, Hantraye P, Brouillet E, Fernandez-Ruiz J (2003a). Effects of cannabinoids in the rat model of Huntington's disease generated by an intrastriatal injection of malonate. Neuroreport 14 : 813 816.
35. Lastres-Becker I, de Miguel R, De Petrocellis L, Makriyannis A, Di Marzo V, Fernandez-Ruiz J (2003b). Compounds acting at the endocannabinoid and/or endovanilloid systems reduce hyperkinesia in a rat model of Huntington's disease. J Neurochem 84 : 1097 1109.
36. Lehrach H, Wanker EE (2001). Huntington's disease: from gene to potential therapy. Dialogues Clin Neurosci 3 : 17 23.
37. Rasband WS (1997-2009). ImageJ, 1.34s edn. Bethesda, Maryland, USA: U. S. National Institutes of Health [WWW document]. URL http://rsb.info.nih.gov/ij/.
38. Robinson P, Lebel M, Cyr M (2008). Dopamine D1 receptor-mediated aggregation of N-terminal fragments of mutant huntingtin and cell death in a neuroblastoma cell line. Neuroscience 153 : 762 772.
39. Ross CA, Margolis RL (2001). Huntington's disease. Clin Neurosci Res 1 : 142 152.
40. Saidak Z, Blake-Palmer K, Hay DL, Northup JK, Glass M (2006). Differential activation of G-proteins by mu-opioid receptor agonists. Br J Pharmacol 147 : 671 680.
41. Sanchez I, Mahlke C, Yuan J (2003). Pivotal role of oligomerization in expanded polyglutamine neurodegenerative disorders. Nature 421 : 373 379.
42. Scherzinger E, Sittler A, Schweiger K, Heiser V, Lurz R, Hasenbank R et al. (1999). Self-assembly of polyglutamine-containing huntingtin fragments into amyloid-like fibrils: implications for Huntington's disease pathology. Proc Natl Acad Sci USA 96 : 4604 4609.
43. Scotter EL, Narayan P, Glass M, Dragunow M (2008). High throughput quantification of mutant huntingtin aggregates. J Neurosci Methods 171 : 174 179.
44. Spires TL, Grote HE, Varshney NK, Cordery PM, van Dellen A, Blakemore C et al. (2004). Environmental enrichment rescues protein deficits in a mouse model of Huntington's disease, indicating a possible disease mechanism. J Neurosci 24 : 2270 2276.
45. Steffan JS, Bodai L, Pallos J, Poelman M, McCampbell A, Apostol BL et al. (2001). Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila. Nature 413 : 739 743.
46. Suhr ST, Gil EB, Senut MC, Gage FH (1998). High level transactivation by a modified Bombyx ecdysone receptor in mammalian cells without exogenous retinoid X receptor. Proc Natl Acad Sci USA 95 : 7999 8004.
47. Takashima A, Koike T (1985). Relationship between dopamine content and its secretion in PC12 cells as a function of cell growth. Biochim Biophys Acta 847 : 101 107.
48. Wachtel SR, White FJ (1995). The dopamine D1 receptor antagonist SCH 23390 can exert D1 agonist-like effects on rat nucleus accumbens neurons. Neurosci Lett 199 : 13 16.
49. Walsh DM, Selkoe DJ (2004). Oligomers on the brain: the emerging role of soluble protein aggregates in neurodegeneration. Protein Pept Lett 11 : 213 228.
50. Watase K, Weeber EJ, Xu B, Antalffy B, Yuva-Paylor L, Hashimoto K et al. (2002). A long CAG repeat in the mouse Sca1 locus replicates SCA1 features and reveals the impact of protein solubility on selective neurodegeneration. Neuron 34 : 905 919.